Vir Biotechnology price target lowered to $26 from $28 at Barclays
The Fly

Vir Biotechnology price target lowered to $26 from $28 at Barclays

Barclays analyst Gena Wang lowered the firm’s price target on Vir Biotechnology (VIR) to $26 from $28 and keeps an Overweight rating on the shares post the Q3 report. The firm expects multiple data updates to provide near-term upside, with “strong balance sheet supporting long-term growth.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App